Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Unknown 2Completed 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Conditions

Warts 1

Interventions

Cryotherapy 7resiquimod 6Cantharidin 4Cholecalciferol 3PRA1 protein, Candida albicans 2N-phenylacetoaminomethylene-DL-p-nitrophenylalanine 2Measles-Mumps-Rubella Vaccine 22-Propanol 2plerixafor 1methyl 5-aminolevulinate 1lactic acid, salicylic acid drug combination 1green tea extract polyphenone E 1gluconic acid 1ammonium trichloro(dioxoethylene-O,O'-)tellurate 1VP-102 1Tuberculin 1Trichloroacetic Acid 1Sugars 1Starch 1Photochemotherapy 1Nitric Oxide 1Mass Screening 1Maltose 1Lasers, Solid-State 1Lasers 1Interferon-alpha 1Imiquimod 1Human Papillomavirus Recombinant Vaccine nonavalent 1Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 1Granulocyte Colony-Stimulating Factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Warts × Tuberculin × Clear all
NCT05254561 2022-02-24

Triple Antigen vs Monoantigen Immunotherapy for Warts

Zagazig University

Phase 2/3 Completed
160 enrolled

Warts

Data powered by HemOnc (CC BY 4.0) Colophon âš¡